← Eichor
Study identifier: NCT06078735 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study

Condition: Atrial Fibrillation · Hemostasis  ·  Sponsor: Kansas City Heart Rhythm Research Foundation

PhaseNA
Planned participants110
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The LockeT II study is a single center, prospective randomized study. It is intended to study the effectiveness of using LockeT device to gain hemostasis after venous procedures as compared to Manual Compression (MC). Approximately 110 patients will be enrolled.

This description comes directly from the study's public registry record.

Talk to the study team

Donita Atkins  ·  816-651-1969  ·  Datkins@kchrf.com

Always discuss trial participation with your own doctor first.

Locations (6)

Kansas City Heart Rhythm Institute - Roe ClinicOverland Park, Kansas, United StatesRecruiting
Overland Park Regional Medical CenterOverland Park, Kansas, United StatesRecruiting
Centerpoint Medical Center ClinicIndependence, Missouri, United StatesRecruiting
Centerpoint Medical CenterIndependence, Missouri, United StatesRecruiting
Research Medical Center ClinicKansas City, Missouri, United StatesRecruiting
Research Medical CenterKansas City, Missouri, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06078735